Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

monoclonal antibody DR-01

A human non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against an as of yet undisclosed cell surface receptor expressed on cytotoxic cells, with potential immunomodulatory and antineoplastic activities. Upon administration, monoclonal antibody DR-01 binds to the as of yet undisclosed cell surface receptor expressed on cytotoxic cells and induce antibody-dependent cellular cytotoxicity (ADCC) against these cytotoxic cells. This may reduce tumor cell proliferation of certain leukemias and lymphomas, and modulate immune responses in certain autoimmune conditions.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	DR 01 DR-01 DR01

monoclonal antibody DR-01

Search NCI's Drug Dictionary